Clinical Trial

Sugammadex Reduces Antiemetic Effect of Dexamethasone

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 30, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Sugammadex is a medication used for reversal of muscle relaxation during procedures under general anesthesia. It works by encapsulating muscle relaxant molecules with a steroid ring in its structure. On the other hand, postoporative nause and vomiting (PONV) is an adverse outcome during anesthesia. PONV can be prevented with pharmacologic agents such as ondansetron and dexamethasone. Dexamethasone is a steroidal agent that can interact with sugammadex. In theory, this interaction could lead to reduced effectiveness of sugammadex. In fact, several studies have explored this interaction. However, the effect of sugammadex on the antiemetic effect of dexamethasone has not been evaluated. This study intends to evaluate this interaction.
Trial Details
NCT Number NCT06901596
Lead Sponsor Augusta University
Conditions PONV
Enrollment 100 participants
Start Date 2025-04-01
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-07-15 (estimated)
Updated on ClinicalTrials.gov 2025-03-30